SummaryCapivasertib is taken as a twice-daily pill, in combination with the hormone therapy fulvestrant. The drug works by blocking an abnormal protein—a part of the cancer cell’s signaling system—that tells the cells to multiply. By disrupting this signal, capivasertib slows or halts the progression of the disease.